CDK1 and neoplasm: We have verified that AS/BJO-NEs can play an anti-tumor role by down-regulating CDK1 and subsequently reducing the expression of MTFR2, as well as inhibiting the proliferation, migration and invasion capabilities of OSCC cells and the EMT process.